Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Madrigal Pharmaceuticals (NASDAQ:MDGL), a biopharmaceutical company specializing in MASH therapeutics, announced the granting of equity inducement awards to 26 new non-executive employees under its 2025 Inducement Plan. The awards include options to purchase 1,984 shares at $302.17 per share and 9,727 time-based restricted stock units.

The equity grants, approved by Madrigal's independent Compensation Committee under Nasdaq Rule 5635(c)(4), include a vesting schedule where 25% of options vest after one year, followed by 6.25% quarterly thereafter. Restricted stock units vest equally over four years, contingent on continued employment.

News Market Reaction

+1.00%

1 alert

+1.00% News Effect

On the day this news was published, MDGL gained 1.00%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

CONSHOHOCKEN, Pa., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on August 1, 2025 to 26 new non-executive employees as equity inducement awards under the terms of Madrigal’s 2025 Inducement Plan. The equity awards were approved by Madrigal’s independent Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4).

The equity awards were granted as inducement material to employees’ acceptance of employment with the company. The new employees received, in the aggregate, options to purchase 1,984 shares of Madrigal’s common stock, and in the aggregate 9,727 time-based restricted stock units. Options have an exercise price of $302.17 per share, which is equal to the closing price of the company’s common stock on the grant date. Options vest as follows: (i) 25% of the option shares will vest on the first anniversary of the grant date and (ii) 6.25% of the option shares will vest on each quarterly anniversary following the first anniversary of the grant date. All restricted stock units granted vest in four equal installments on each of the first through fourth anniversaries of the grant date. The vesting of all awards described above shall be subject to each such employee’s continued employment as of the applicable vesting date.

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. Madrigal’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra is the first and only medication approved by the FDA for the treatment of MASH with moderate to advanced fibrosis (consistent with stages F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (consistent with stage F4c). For more information, visit www.madrigalpharma.com.

Investor Contact
Tina Ventura, IR@madrigalpharma.com

Media Contact
Christopher Frates, media@madrigalpharma.com

FAQ

What equity awards did Madrigal Pharmaceuticals (MDGL) grant to new employees in August 2025?

Madrigal granted options to purchase 1,984 shares at $302.17 per share and 9,727 restricted stock units to 26 new non-executive employees.

What is the vesting schedule for Madrigal's (MDGL) 2025 inducement awards?

Options vest 25% after one year and 6.25% quarterly thereafter. Restricted stock units vest in four equal annual installments over four years.

How many new employees received inducement awards from Madrigal Pharmaceuticals in August 2025?

26 new non-executive employees received equity inducement awards under Madrigal's 2025 Inducement Plan.

What was the exercise price for Madrigal's (MDGL) stock options granted in August 2025?

The options were granted with an exercise price of $302.17 per share, equal to the closing price on the grant date of August 1, 2025.